NCT00515502 - Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2007

Primary Completion Date

November 6, 2007

Study Completion Date

November 6, 2007

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719

250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

DRUG

Tiotropium

strips of five capsules, each containing 18 μg administered via dry powder inhaler

Trial Locations (3)

GSK Investigational Site, Berlin

GSK Investigational Site, Hamburg

GSK Investigational Site, Hanover